

Disclaimer

It is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

·Jeisys Medical announces all-time high sales and operating profit in 2023 to KRW 143.0bil and KRW 36.3bil respectively

Jeisys Medical posted its record-high sales and operating profit of KRW 143.0bil and KRW 36.3bil respectively, backed by robust RF demand and accelerated consumables sales

The company's prominent minimally-invasive RF device POTENZA has reached over 3,000 units of accumulated sales and further strengthened its global presence in medical aesthetics market. Number of POTENZA sold in domestic market has also surpassed 200 units

The company's non-invasive RF device DENSITY was successfully launched in Korea (Apr'23), US (Sep'23) and Japan (Dec'23) and rapidly grew globally through our own unique technical competitiveness

In terms of Consumables, both cartridge and tip sales showed meaningful increase in line with rising device sales and treatments growth. Demand of skin booster also soared backed by rising customers' appetite of POTENZA pumping tip + skin booster combination

2023 Brief Summary

1. Sales : Total sales reached KRW 143.0bil +22.7% YoY with fast-growing RF devices and consumables
2. Gross Profit : Through consistent cost-reduction efforts, gross profit recorded KRW 99.0bil, +24.4% YoY and gross profit margin remained around 70%,
3. Operating Profit : Operating profit recorded all-time high figures to KRW 36.3bil, +6.7% YoY. Despite record-high sales and GP Margin, OP Margin declined to 25.4% from 29.2% YoY due to one-off cost
* one-off cost : KRW 5.4bil for ITC litigation and stock option cost
4. Net Profit : Additional corporate tax recognition when stock option exercis resulted in net profit decline YoY
- '23 Net profit : KRW 25.1bil (vs. KRW 27.0bil)

I. Sales


RF sales posted KRW 41.7bil, +33% YoY with robust POTENZA sales and successful launch of DENSITY in major markets. HIFU sales was KRW 15.1bil, -12% YoY due to intensified competition. Laser and IPL also went down by 9% and 1% to KRW 5.4bil and KRW 10.8bil respectively

① Sales Breakdown by Product

'23 Sales Breakdown : RF 29%, HIFU 11%, IPL 4%, LASER 8%, Consumables 40%, Others 9%



- Domestic : RF 45%, HIFU 8%, IPL 6%, LASER 0%, Consumables 40%, Others 1%

- Overseas : RF 26%, HIFU 11%, IPL 3%, LASER 9%, Consumables 40%, Others 10%




② Sales Breakdown by Region

- '23 Sales Breakdown by Region : Domestic 19% vs. Overseas 81%




II. Gross Profit

Through cost reduction efforts, gross profit in 2023 reached KRW 99.0bil, +24.4% YoY. Gross profit margin in 2023 also increased to 69.2% from 68.3% in 2022



III. Operating Profit

Operating profit in 2023 enhanced by 6.7% to KRW 36.3bil, hitting its record-high. However operating profit margin in 2023, declined by 3.8% point on year to 25.4% mainly due to one-off cost



IV. Net Income

Net Income in 2023 declined by 7.0% YoY to KRW 25.1bil due to deferred tax liability related to stock option being recognized as corporate tax at once

► Brief Financial Summary (K-IFRS)

(Unit : KRW)	2022	2023	YoY
Sales	116,549,559,691	143,029,552,904	22.7%
Cost of goods sold	36,974,583,991	44,059,531,300	19.2%
Gross Profit	79,574,975,700	98,970,021,604	24.4%
SG&A	45,539,813,623	62,656,269,545	37.6%
Operating Profit	34,035,162,077	36,313,752,059	6.7%
Net Income before Tax	33,888,026,567	35,498,347,318	4.8%
Net Income	27,012,265,584	25,107,906,079	-7.0%